Verus Capital Partners LLC Purchases Shares of 2,966 DexCom, Inc. (NASDAQ:DXCM)

Verus Capital Partners LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 2,966 shares of the medical device company’s stock, valued at approximately $336,000.

Other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC purchased a new stake in shares of DexCom during the 4th quarter valued at $1,986,000. Gilbert & Cook Inc. grew its stake in shares of DexCom by 8.2% during the 4th quarter. Gilbert & Cook Inc. now owns 3,431 shares of the medical device company’s stock valued at $426,000 after buying an additional 261 shares during the period. 9258 Wealth Management LLC purchased a new stake in shares of DexCom during the 4th quarter valued at $286,000. Axxcess Wealth Management LLC purchased a new stake in shares of DexCom during the 4th quarter valued at $208,000. Finally, Private Advisor Group LLC grew its stake in shares of DexCom by 27.6% during the 4th quarter. Private Advisor Group LLC now owns 10,772 shares of the medical device company’s stock valued at $1,337,000 after buying an additional 2,329 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on DXCM. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Stifel Nicolaus upped their price target on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. JPMorgan Chase & Co. cut shares of DexCom from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $145.00 to $75.00 in a research report on Friday, July 26th. UBS Group decreased their price target on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Finally, BTIG Research decreased their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $112.25.

Insider Activity

In other news, CFO Jereme M. Sylvain sold 745 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $85,712.25. Following the sale, the chief financial officer now owns 84,948 shares in the company, valued at approximately $9,773,267.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CFO Jereme M. Sylvain sold 745 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $85,712.25. Following the sale, the chief financial officer now owns 84,948 shares in the company, valued at approximately $9,773,267.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Sadie Stern sold 427 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now owns 75,877 shares in the company, valued at approximately $8,729,648.85. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,483 shares of company stock worth $369,052. 0.30% of the stock is currently owned by corporate insiders.

DexCom Stock Performance

NASDAQ:DXCM opened at $72.36 on Wednesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The firm has a 50-day moving average of $90.10 and a two-hundred day moving average of $114.21. The stock has a market cap of $28.78 billion, a P/E ratio of 46.68, a PEG ratio of 2.15 and a beta of 1.16. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.34 EPS. On average, research analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.